Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2071250073) titled 'ALKAZAR' on Sept. 25.
Study Type: Interventional
Study Design:
randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose
Primary Sponsor: Tsutsui Toshio
Condition:
Advanced ALK-positive non-small cell lung cancer
Intervention:
Patients will receive 150 mg of NVL-655 orally once daily, or 600 mg of Alectinib orally twice daily, and continue treatment until symptomatic deterioration, development of unacceptable toxicity, or other discontinuation criteria are met. The dose should be reduced accordingly based on the patients condition.
Recruitment Status: N...